Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, announced today the closing of its previously announced registered direct offering with several institutional investors of 2,090,909 shares of its common stock at a purchase price of $2.75 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $5.75 million, before deducting placement agent fees and offering expenses.
Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has priced a public offering of an aggregate of 7,142,858 shares of common stock (or common stock equivalents) of the Company and warrants to purchase up to 7,142,858 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock, at a public offering price of $1.05 per share and accompanying warrant. The shares of common stock (or common stock equivalents) and the accompanying warrants are being sold together in this offering, but will be issued separately and will be immediately separable upon issuance. The warrants are exercisable immediately and expire five years from the date of issuance. Each warrant has an exercise price of $1.05.
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the record date and distribution date to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") will be deferred because of the requirement that the shares be registered prior to distribution. AIkido will provide a record date and distribution date for the distribution of the shares promptly once the registration statement is declared effective and will issue an update to shareholders in two weeks on the status of this matter.
Spherix Incorporated (Nasdaq: SPEX) today announced that it has redesigned the company's website (www.spherix.com) to illuminate the overall digital transformation and recently acquired anti-cancer therapeutics. The new digital platform will emphasize on technology acquired from world renowned institutions such as The University of Texas and Wake Forest University. Our diverse portfolio of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Treatments such as the DHA-dFdC identified by The University of Texas, has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic models. In addition, Wake Forest University has provided a method of treatment for (AML) and (ALL) with the drug KPC-34. The launch of our redesigned website will reflect Spherix ongoing commitment to research in biotechnology development and oncological treatment.
Spherix Incorporated (Nasdaq: SPEX) ("Spherix" or the "Company") today announced that on March 13, 2020, the Company will officially change its name to AIkido Pharma Inc. ("AIkido"). Effective at the start of trading on March 13, 2020, the Company's shares will trade on the Nasdaq Capital Market under the new name and the new stock symbol will be "AIKI". The name change reflects the Company's increased commitment to the use of artificial intelligence and machine learning in the drug development space.
Benzinga Pro's Stocks To Watch For Monday * ExxonMobil (XOM) \- Shares were down nearly 14% as the price of crude oil fell more than $9/barrel. Saudi officials decided to instigate a price war by cutting production over the weekend. Crude oil last traded around $32/barrel. * SPDR Gold ETF (GLD) \- This ETF was up about 0.3% in opposition to the move in oil. Gold also benefited amid reports the number of coronavirus cases confirmed outside China nearly tripled since last week. * Boeing (BA) \- The stock was down about 9% following a report the FAA may require the company to fix electrical wire issues before the 737 MAX can return to flight. * Tesla (TSLA) \- A weekend article from the FT suggested notable investor James Anderson, head of global equities for Baillie Gifford (Tesla's largest shareholder), said he was now "more comfortable" with the company following a recent management shuffle. Anderson called the appointment of Robyn Denholm, an independent board member since 2014, a "decisive move." * Spherix (SPEX) \- A new coronavirus play as of Friday, shares continued higher Monday morning. After closing up 131% on Friday, shares were up another 60% Monday morning. On Friday, the company announced the execution of exclusive option deal with University of Maryland for "Methods of Treating Coronavirus Infection" patent.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 18, 2020: AAPL, WMT, TSLA, FLR, SPWR * Benzinga Pro's Top 5 Stocks To Watch For Fri., Feb. 14, 2020: TSLA, ROKU, CRON, YELP, AMD * Benzinga Pro's Top 5 Stocks To Watch For Thurs., Feb. 13, 2020: FXI, TSLA, BABA, NIO, CAT(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,090,909 shares of Spherix's common stock, at a purchase price of $2.75 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about March 11, 2020, subject to the satisfaction of customary closing conditions.
AIkido Pharma Incorporated (Nasdaq: AIKI) today provided an update onto shareholders as follows:
Spherix Incorporated (Nasdaq: SPEX) today announced it has executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center with the goal of using machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated (Nasdaq: SPEX) announced that, in light of the expected closing of its public offering tomorrow, March 5, 2020, the record date with respect to the Hoth dividend has been moved to Friday, March 6, 2020, so that its new shareholders may participate in the Hoth dividend.
AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced that its Board of Directors (the "Board") has acted to preserve and protect the Company's valuable income tax net operating loss carryforwards ("NOLs") by adopting a stockholder rights plan in the form of a Section 382 Rights Agreement, dated as of March 23, 2020, by and between the Company and VStock Transfer LLC (the "Stockholder Rights Plan").
AIkido Pharma Incorporated (Nasdaq: AIKI) today provided an update on the recently announced Coronavirus technology optioned by the Company.
Spherix Incorporated (Nasdaq: SPEX) today announced that it has closed the CBM BioPharma, Inc. transaction and is working to develop these cancer drugs.
Anthony Hayes has been the CEO of Spherix Incorporated (NASDAQ:SPEX) since 2013. This analysis aims first to contrast...
Spherix Incorporated (Nasdaq: SPEX) today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix.
Spherix Incorporated (NASDAQ: SPEX), a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders:
Spherix Incorporated (Nasdaq: SPEX) today provided an update on the recently announced treatment for Coronavirus technology optioned by the Company.
Spherix Incorporated (Nasdaq: SPEX) today announced its attendance at the AI & ML Drug Discovery Summit. The AI-ML in Drug Development Summit is the only conference to bring together industry leaders, technology experts and academics focused on augmenting the R&D; processes through the use of Artificial Intelligence and Machine Learning. The event, scheduled for February 24-26, 2020 at the DoubleTree by Hilton Hotel San Diego - Mission Valley, brings together industry leaders and academics who are developing and implementing technological solutions for some of pharma's greatest problems.
Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the University of Maryland, Baltimore for the technology in the patent for "Methods of Treating Coronavirus Infection." Trading volume swelled to 2.2 million shares, already more than the full-day average of 1.2 million shares. The company said the invention was made with support awarded by the National Institutes of Health, which has certain rights in the invention. Under terms of the option, Spherix said it has until the end of May to execute a license agreement for commercial development. The stock has lost 23% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 2.5% and the S&P 500 has shed 6.9%.
Spherix Incorporated (Nasdaq: SPEX) today announced it has executed an exclusive option agreement ("Option") with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 "Methods of Treating Coronavirus Infection." The present invention provides methods for treating a coronavirus infection.